Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.64 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | FPR2 | P25090 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | ACACB | O00763 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | IL2 | P60568 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361126 | 1.00 | ITGB3 (0.64) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL10660397 | 1.00 | ITGB3 (0.64) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL27850537 | 0.96 | ITGB3 (0.60) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL27850539 | 0.96 | ITGB3 (0.60) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL16587684 | 0.91 | ITGB3 (0.55) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL12330296 | 0.89 | ACACB (0.59) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL8765951 | 0.88 | LDHA (0.63) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL10663117 | 0.88 | LDHA (0.63) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL5706152 | 0.88 | ACACB (0.58) | ITGB3ITGA2BLDHAFPR2KMT2A | |
| SCHEMBL6662892 | 0.88 | ACACB (0.58) | ITGB3ITGA2BLDHAFPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| US-4111923-A | LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS | PARKE, DAVIS & COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ITGB3 199/4885ITGA2B 282/4885LDHA 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.